INFO: Second infection of HCV during IFN therapy (via IV drug use)
Question:
for what she lacks in brains, she made up in luck. definitely a darwin award nominee. Dez "Russ Tanner" <sourdo55 at yahoo.com> wrote in message news:vheohg8sn8498@corp.supernews.com… – Hide quoted text — Show quoted text -> christ, how stupid could you be to shoot drugs with a dirty needle while on > therapy for HCV???? Some people are something else…. > — > Russ Tanner > Palmer, Alaska > email address is spoofed, you’ll figure it out! > http://www.tannersacre.com > "Kim" <hepautoma…@hotmail.com> wrote in message > news:ec181702.0307161933.3674645d@posting.google.com… > > Second infection with a different hepatitis C virus genotype in a > > intravenous drug user during interferon therapy. > > Gut. 2003 Jun;52(6):900-2. > > Asselah T, Vidaud D, Doloy A, Boyer N, Martinot M, et al. > > Service d’Hepatologie, INSERM U 481 and Centre de Recherche > > Claude > > Bernard sur les Hepatites Virales, Clichy, France. > > The prevalence of antibodies against hepatitis C virus > > (anti-HCV) > > among intravenous drug users (IVDU) has consistently been very high. > > Cross > > challenge studies in chimpanzees provide evidence that reinfection with > > different HCV strains may occur. In humans, reinfection with different > > HCV > > strains has been reported in multitransfused haemophiliacs and recently > > in > > IVDU but no case has been reported while on interferon (IFN) therapy. > > We report on a 22 year old woman who was treated with IFN alpha > > for > > HCV genotype 3a chronic infection. At six months, HCV RNA was > > undetectable > > by reverse transcription-polymerase chain reaction. In October 1997, > > while > > still on IFN, she developed an acute hepatitis after an intravenous > > drug > > injection and HCV genotype 1a infection was identified using genotyping > > and > > sequencing methods. IFN therapy was continued until August 1998, and in > > January 1999 HCV-RNA was not detectable. > > Our case indicates that the previous HCV infection might have > > prevented development of chronicity. An alternative explanation is that > > IFN, while not preventing acute hepatitis C, may prevent chronicity. > > The > > risk of multiple infection in IVDU underlines the need for preventive > > strategies.
Posted Via Usenet.com Premium Usenet Newsgroup Services ———————————————————- ** SPEED ** RETENTION ** COMPLETION ** ANONYMITY ** ———————————————————- http://www.usenet.com
Response:
christ, how stupid could you be to shoot drugs with a dirty needle while on therapy for HCV???? Some people are something else…. — Russ Tanner Palmer, Alaska email address is spoofed, you’ll figure it out! http://www.tannersacre.com "Kim" <hepautoma…@hotmail.com> wrote in message
news:ec181702.0307161933.3674645d@posting.google.com… – Hide quoted text — Show quoted text -> Second infection with a different hepatitis C virus genotype in a > intravenous drug user during interferon therapy. > Gut. 2003 Jun;52(6):900-2. > Asselah T, Vidaud D, Doloy A, Boyer N, Martinot M, et al. > Service d’Hepatologie, INSERM U 481 and Centre de Recherche > Claude > Bernard sur les Hepatites Virales, Clichy, France. > The prevalence of antibodies against hepatitis C virus > (anti-HCV) > among intravenous drug users (IVDU) has consistently been very high. > Cross > challenge studies in chimpanzees provide evidence that reinfection with > different HCV strains may occur. In humans, reinfection with different > HCV > strains has been reported in multitransfused haemophiliacs and recently > in > IVDU but no case has been reported while on interferon (IFN) therapy. > We report on a 22 year old woman who was treated with IFN alpha > for > HCV genotype 3a chronic infection. At six months, HCV RNA was > undetectable > by reverse transcription-polymerase chain reaction. In October 1997, > while > still on IFN, she developed an acute hepatitis after an intravenous > drug > injection and HCV genotype 1a infection was identified using genotyping > and > sequencing methods. IFN therapy was continued until August 1998, and in > January 1999 HCV-RNA was not detectable. > Our case indicates that the previous HCV infection might have > prevented development of chronicity. An alternative explanation is that > IFN, while not preventing acute hepatitis C, may prevent chronicity. > The > risk of multiple infection in IVDU underlines the need for preventive > strategies.
Response:
Second infection with a different hepatitis C virus genotype in a intravenous drug user during interferon therapy. Gut. 2003 Jun;52(6):900-2. Asselah T, Vidaud D, Doloy A, Boyer N, Martinot M, et al. Service d’Hepatologie, INSERM U 481 and Centre de Recherche Claude Bernard sur les Hepatites Virales, Clichy, France. The prevalence of antibodies against hepatitis C virus (anti-HCV) among intravenous drug users (IVDU) has consistently been very high. Cross challenge studies in chimpanzees provide evidence that reinfection with different HCV strains may occur. In humans, reinfection with different HCV strains has been reported in multitransfused haemophiliacs and recently in IVDU but no case has been reported while on interferon (IFN) therapy. We report on a 22 year old woman who was treated with IFN alpha for HCV genotype 3a chronic infection. At six months, HCV RNA was undetectable by reverse transcription-polymerase chain reaction. In October 1997, while still on IFN, she developed an acute hepatitis after an intravenous drug injection and HCV genotype 1a infection was identified using genotyping and sequencing methods. IFN therapy was continued until August 1998, and in January 1999 HCV-RNA was not detectable. Our case indicates that the previous HCV infection might have prevented development of chronicity. An alternative explanation is that IFN, while not preventing acute hepatitis C, may prevent chronicity. The risk of multiple infection in IVDU underlines the need for preventive strategies.
